GALWAY, Ireland, March 28,
2024 /PRNewswire/ -- Neurent Medical, a company
pioneering innovative non-surgical interventions to treat chronic
inflammatory sinonasal diseases, today announced the appointment of
Mr. John Peterson as the new Vice
President of Sales & Marketing, effective immediately.
I'm extremely honored to join the talented
Neurent Medical team at this exciting time of growth for the
Company.
Bringing over a decade of invaluable experience in the medical
device industry, Mr. Peterson joins Neurent Medical with a robust
background in sales management, strategy, product marketing,
business development, and finance. Most recently, he spearheaded
sales and business development initiatives at Tactile Medical. Mr.
Peterson has significant expertise in the ear, nose and throat
(ENT) sector, having held key positions including VP of Business
Development at Entellus Medical during their acquisition of Spirox
and their subsequent acquisition by Stryker, and Director of
Business Development and Portfolio Strategy for Stryker ENT, where
he played a pivotal role in the acquisition of Arrinex.
Expressing enthusiasm for his new role, Mr. Peterson remarked, "I'm
extremely honored to join the talented Neurent Medical team at this
exciting time of growth for the Company. I look forward to
supporting the strong momentum the team has established to date
while working closely with the ENT community to drive more
awareness to the space, establishing NEUROMARK® as the
treatment of choice for practices to bring relief to the millions
of patients that suffer from chronic rhinitis."
In his new capacity, Mr. Peterson will assume full responsibility
for the commercialization of the NEUROMARK System, collaborating
closely with both R&D and Clinical teams to maximize the market
potential of the procedure. His strategic vision and leadership
will play a crucial role in further developing Neurent Medical's
portfolio of products and therapies.
Brian Shields, CEO of Neurent
Medical, expressed his confidence in Mr. Peterson's appointment,
stating, "Our people continue to be our biggest asset at Neurent
Medical and John adds considerable value to the growing team. He
joins us at a pivotal time in our development as we drive growth to
expand our presence and market share. I am looking forward to
working closely with him as we continue to support our customers
efforts to positively impact the lives of their patients."
Mr. Peterson's comprehensive skill set and proven track record
make him an ideal fit for his new role, perfectly aligned
with Neurent Medical's mission to revolutionize treatment
options for chronic nasal conditions. He holds a Bachelor's degree
in Biology and Economics from St. Olaf
College.
The NEUROMARK System has received U.S. Food and Drug
Administration (FDA) 510(k) clearance and Neurent Medical announced
the limited market release of the system in 2023.
About Neurent Medical
Neurent Medical is pioneering innovative treatments for chronic
inflammatory sinonasal diseases by targeting and safely disrupting
hyperactive autonomic nerves that drive underlying inflammation.
Its proprietary NEUROMARK® technology with a unique
design and advanced smart algorithmic control, allows physicians to
precisely target and safely disrupt multiple underlying nerve
branches in a single procedure to alleviate chronic rhinitis
symptoms and improve patient quality of life. The venture
capital-backed company is headquartered in Galway, Ireland, with US HQ in Braintree, MA. For more information visit
www.neurentmedical.com.
PAM121r01 Mar 2024
View original content to download
multimedia:https://www.prnewswire.com/news-releases/neurent-medical-welcomes-john-peterson-as-vp-of-sales--marketing-302102708.html
SOURCE Neurent Medical